Judging a Fish by Its Ability to Climb a Tree? A Call for Novel Endpoints in the Appraisal of Ablative Local Treatments of Oligometastatic Cancer.

This commentary addresses the need for novel endpoints in clinical research to assess the added value of local treatment of metastases in oligometastatic patients and in patients experiencing limited metastatic progression during systemic therapy (oligoprogressive). Novel metrics are proposed for future implementation in clinical trials.